Alkermes plc. (ALKS) Stock
1 member of Congress disclosed 2 trades in ALKS since 2026: 2 purchases and 0 sales, most recently Gilbert Cisneros (purchase, Sep 29, 2026). Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
Which members of Congress traded Alkermes plc. (ALKS)?
Most recent: Gilbert Cisneros (purchase, Sep 29, 2026); records start Jul 30, 2026.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-09-29 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-07-30 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all ALKS political trades →Are Alkermes plc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2.0K | $94K |
| Oct 2, 26 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2.0K | $83K |
| Sep 3, 26 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2.0K | $98K |
| Sep 1, 26 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | SELL | 9.0K | $423K |
| Aug 17, 26 | Nichols Christian Todd | SVP, Chief Commercial Officer | SELL | 6.9K | $340K |
| Aug 17, 26 | Nichols Christian Todd | SVP, Chief Commercial Officer | SELL | 664 | $33K |
| Aug 3, 26 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | SELL | 2.0K | $99K |
| Aug 3, 26 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | SELL | 9.0K | $437K |
| Aug 3, 26 | Snyderman Nancy Lynn Md | Director | SELL | 44.5K | $2.2M |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →ALKS price chart
Powered by TradingViewWhat does Alkermes plc. do?
Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.